Skip to content

The Black Book of Psychotropic Dosing and Monitoring.

Justin Faden, Leslie Citrome

Psychopharmacology Bulletin July 8, 2024 DOI: 10.1177/2045125320968658 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Commentary Peer reviewed
Interventions Bupropion Dextromethorphan
Topics Psychedelic-assisted therapy
Keywords Mental health treatment Psychiatric medication Breakthrough therapies Clinical research
Citations 29
Key points The text reports that several innovative psychiatric agents have been approved or are near approval, including novel antidepressants, a first-in-class muscarinic agonist for schizophrenia, a psychedelic that may be approved for PTSD, and a first disease-modifying Alzheimer's drug. Three new antidepressants launched in the past 18 months; Auvelity, combining bupropion and dextromethorphan, is said to exploit synergy between the two drugs.

Abstract

Since the last edition of the Black Book, several innovative agents have been approved or are poised to be approved in the coming year. These include novel antidepressants, the first muscarine agonist for the treatment of schizophrenia, the first psychedelic which may be approved for the treatment of PTSD (Post Traumatic Stress Disorder), and the first disease modifying drug for the treatment of Alzheimer's disease. Three new antidepressants have come to the market in the past 18 months. The first of those, Auvelity, the combination of bupropion and dextromethorphan, takes advantage of a pharmacokinetic and pharmacodynamic synergism between the two drugs.

Citations in the library

Cited by 4

Related reading

Explore topics

Psychedelic-assisted therapy PTSD